International Review of Ophthalmology ›› 2024, Vol. 48 ›› Issue (6): 476-480.doi: 10.3760/ cma.j.issn.1673-5803.2024.06.015

Previous Articles    

Current status of intra-arterial chemotherapy for retinoblastoma

Sun Fanqi1, Guo Xiaoxuan1, Gu Huali2   

  1. 1 Capital Medical University Forth Clinical School, Beijing 100730, China; 2 Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
  • Received:2024-06-25 Online:2024-12-22 Published:2024-12-06
  • Contact: Gu Huali, Email: hlgu0217@163.com
  • Supported by:
    Capital’s Funds for Health Improvement and Research (2024-2-2056);Beijing Municipal Administration of Hospitals Incubating Program (pX2022005); Undergraduate Research Innovation Project of Capital Medical University (XSKY2024348）

Abstract: Retinoblastoma (RB), a common malignant tumor of the eye in children, has been continuously evolving in its treatment methods as medical technology advances and greater attention is paid to patients' quality of life. In recent years, intra-arterial chemotherapy (IAC) has become an important treatment modality for RB, achieving targeted local chemotherapy of the tumor through ophthalmic artery drug delivery, significantly improving treatment outcomes and reducing systemic adverse reactions. This article provides a comprehensive review of the technical operation, chemotherapeutic drugs (melphalan, carboplatin, topotecan), eye and systemic adverse reactions, prognosis, and limitations of IAC in the treatment of RB, aiming to provide reference value for the improvement and development of IAC in clinical practice. (Int Rev Ophthalmol, 2024, 48:  476-480)

Key words: retinoblastoma; , interventional therapy； intra-arterial chemotherapy